Tables turned? Cambridge pharma firm launches hostile bid for New York-listed peer Pharma Vanda Pharmaceuticals, based in Washington DC, confirmed the receipt of Cycle’s “unsolicited, non-binding indication of interest” and stated it would carefully review and evaluate the proposal.